Department of Clinical Chemistry and Laboratory Medicine, Saarland University Hospital, Building 57, 66421, Homburg, Saar, Germany.
Fachhochschule des Mittelstands, University of Applied Sciences, 50674, Cologne, Germany.
Aging Clin Exp Res. 2019 Dec;31(12):1817-1825. doi: 10.1007/s40520-019-01125-6. Epub 2019 Jan 24.
Elderly people are at risk for vitamin B12 deficiency.
We studied the ability of vitamin B12-enriched toothpaste vs. placebo to increase vitamin B12 status in elderly subjects.
We conducted a randomized double-blind placebo-controlled intervention in 103 elderly subjects. Serum concentrations of vitamin B12, holotranscobalamin (holoTC), methylmalonic acid (MMA), and plasma total homocysteine (tHcy) were measured at baseline and after 3 months.
92 subjects met the inclusion criteria, completed the 3 months study, and were included in the data analysis. After the intervention, concentrations of vitamin B12 were higher [mean (SD) = 368 (123) vs. 295 (123) pmol/L; p = 0.005] and holoTC tended to be higher [112 (48) vs. 91 (68) pmol/L; p = 0.088] in the vitamin B12 group compared with the placebo group. The changes of serum vitamin B12 [54 (74) vs. 3 (60) pmol/L, p < 0.001], holoTC [21 (34) vs. 2 (32) pmol/L, p = 0.007], and tHcy [- 0.9 (2.3) vs. 0.3 (1.9) µmol/L, p = 0.010] were significantly different between the intervention groups. Mean percentage increase of serum vitamin B12 (+ 23% corresponds to + 54 pmol/L) in the vitamin B12 toothpaste group suggests that the intervention had provided an additional daily intake of approximately + 7 µg oral B12. Common diseases and drugs did not predict the change of blood markers in the vitamin group. No side effects were observed.
The toothpaste enriched with 100 µg cyanocobalamin/g has increased vitamin B12 status and can thus be used for preventing vitamin B12 depletion in elderly people. The trial was registered at ClinicalTrials.gov: NCT02679833.
老年人有维生素 B12 缺乏的风险。
我们研究了富含维生素 B12 的牙膏与安慰剂相比，增加老年受试者维生素 B12 状况的能力。
我们对 103 名老年受试者进行了随机、双盲、安慰剂对照干预。在基线和 3 个月后测量血清维生素 B12、全钴胺素（holoTC）、甲基丙二酸（MMA）和血浆总同型半胱氨酸（tHcy）浓度。
92 名受试者符合纳入标准，完成了 3 个月的研究，并纳入数据分析。干预后，维生素 B12 浓度较高[平均值（标准差）= 368（123）比 295（123）pmol/L；p = 0.005]，且维生素 B12 组的 holoTC 水平趋于升高[112（48）比 91（68）pmol/L；p = 0.088]。血清维生素 B12 的变化[54（74）比 3（60）pmol/L，p<0.001]、holoTC [21（34）比 2（32）pmol/L，p = 0.007]和 tHcy [-0.9（2.3）比 0.3（1.9）µmol/L，p = 0.010]在干预组之间有显著差异。维生素 B12 牙膏组血清维生素 B12 平均增加率（+23%，对应+54 pmol/L）表明，干预措施提供了约额外的每日+7µg 口服 B12 摄入量。常见疾病和药物并不能预测维生素组血液标志物的变化。未观察到副作用。
每克含 100µg 氰钴胺的牙膏增加了维生素 B12 状况，因此可用于预防老年人维生素 B12 耗竭。该试验在 ClinicalTrials.gov 注册：NCT02679833。
